Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi has launched a new clinical study titled ‘A Randomized, ...

Honeysuckle nanovesicles reduced gut inflammation and restored microbial and immune balance in colitis models, suggesting a microbiota-based therapy.

A new animal study sheds light on how a common dietary supplement may ease both gut and brain symptoms of inflammatory bowel ...

Your gut microbiome is comprised of the microscopic life in your digestive tract and all the things they produce. Some studies suggest it might be indicative of your overall health. Harnessing the ...

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 ...

Fecal microbiota, live-jslm ( REBYOTA ® [RBL]) demonstrates a favorable safety profile and treatment effectiveness against recurrent Clostridioides difficile infection (rCDI) in patients with and ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

For decades, scientists have puzzled over why smoking makes Crohn’s disease worse but seems to protect people from ulcerative ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.